Literature DB >> 28314273

Failure of Inositol Trispyrophosphate to Enhance Highly Effective Radiotherapy of GL261 Glioblastoma in Mice.

Sujatha Iyengar1, David Schwartz2.   

Abstract

BACKGROUND/AIM: Inositol trispyrophosphate (ITPP), reported to cure hepatomas in a preclinical rat model and to have beneficial effects in several other solid tumor models, is currently in clinical trial for liver cancer. We investigated whether aggressive glioblastomas could be effectively treated with ITPP alone or in combination with radiation therapy (RT).
MATERIALS AND METHODS: C57Bl/6 mice were intracranially injected with syngeneic GL261 glioblastoma cells and treated with hypofractionated radiation (5 Gy × 3), ITPP, or both. Tumors were followed by imaging, and mice sacrificed due to morbidity or at 90 days, with microscopic examination of brain sections.
RESULTS: RT alone significantly prolonged survival, whereas ITPP alone did not. Surprisingly, ITPP appeared to reduce the effectiveness of RT when added in combination.
CONCLUSION: ITPP was ineffective as monotherapy for glioblastoma and appeared to interfere with the beneficial impact of RT. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  GL261; Glioblastoma; PI3K/AKT; PTEN; hypofractionated radiation; hypoxia; inositol trispyrophosphate

Mesh:

Substances:

Year:  2017        PMID: 28314273     DOI: 10.21873/anticanres.11425

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models.

Authors:  Ly-Binh-An Tran; Thanh-Trang Cao-Pham; Bénédicte F Jordan; Sofie Deschoemaeker; Arne Heyerick; Bernard Gallez
Journal:  J Cell Mol Med       Date:  2018-12-21       Impact factor: 5.310

Review 2.  Interfering with Tumor Hypoxia for Radiotherapy Optimization.

Authors:  Irma Telarovic; Roland H Wenger; Martin Pruschy
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.